文献速递生殖医学

克罗米芬与促性腺激素剂量对低反应者卵巢反应标志物及IVF结局影响的随机对照试验

Randomised controlled trial on the effect of clomiphene citrate and gonadotropin dose on ovarian response markers and IVF outcomes in poor responders.
PubMed 文献 · Hum Reprod · 2021-01-01

该单中心随机双盲试验纳入114名符合Bologna标准的低反应者,比较促性腺激素起始剂量(150 vs 450 IU)及克罗米芬(CC)添加与否对卵巢反应的影响。主要结局获卵数各组无显著差异(P=0.246),但150 IU联合CC组囊胚数显著高于450 IU联合CC组(P=0.006)。总体活产率12.3%,累积活产率14.7%。

要点

  • 促性腺激素起始剂量150与450 IU获卵数无显著差异。
  • 150 IU联合CC组囊胚数显著高于450 IU联合CC组。
  • 添加CC不影响FSH水平,但子宫内膜厚度较低。

核心结论

  • 低反应者中促性腺激素起始剂量和CC添加不影响获卵数,但150 IU联合CC可获更多囊胚。

研究设计与样本

  • 单中心随机双盲临床试验,2013年8月至2017年11月开展,2288例中220例(9.6%)符合Bologna标准,114例随机分四组。

主要发现

  • 获卵数各组相似:A组2.85(95%CI 2.04-3.98),B组4.32(3.31-5.64),C组3.33(2.45-4.54),D组3.22(2.36-4.41),P=0.246。
  • 囊胚数B组1.77(95%CI 1.42-2.22)显著高于A组0.83(0.58-1.2),P=0.006。
  • 150 IU组平均FSH水平较低,添加CC不影响FSH;各组雌二醇无差异,CC组子宫内膜厚度较低。
  • 总体活产率12.3%,累积活产率14.7%。

关键数值与推荐

  • Bologna标准定义低反应者。
  • CC 100 mg从周期第3至7天,HMG起始剂量150或450 IU。
  • 主要结局为获卵数,其他包括卵巢反应、胚胎发育及产科结局。

临床怎么用

  • 低反应者促性腺激素起始剂量150 IU联合CC可能获得更多囊胚。
  • 高剂量(450 IU)升高FSH水平但未增加获卵数或雌二醇。
  • 低起始剂量可降低药物成本。

局限性

  • 研究未针对囊胚数或活产率进行效能计算。
  • 样本量较小,活产率差异需进一步随机试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the gonadotropin (GN) starting dose and the addition of clomiphene citrate (CC) during the early follicular phase influence oocyte yield in poor responders undergoing ovarian stimulation for IVF treatment? SUMMARY ANSWER: The number of retrieved oocytes was similar regardless of the starting dose of GN (150 versus 450 IU) with or without the addition of CC (100 mg from Day 3 to 7 versus placebo). WHAT IS KNOWN ALREADY: ART in poor responders is a challenge for patients and clinicians. So far, randomised controlled studies addressing interventions have shown that neither the GN dose nor the addition of oral medication has any significant effect on the clinical outcome of ART in poor responders. There is limited knowledge about the effect of GN starting dose in combination with CC during the early follicular phase of ovarian stimulation on ovarian response markers and ART outcome. STUDY DESIGN, SIZE, DURATION: This single-centre randomised double-blinded clinical trial was conducted from August 2013 until November 2017. Using the Bologna criteria, 220 of 2288 patients (9.6%) were identified as poor responders and 114 eligible participants underwent ovarian stimulation in a GnRH-antagonist protocol for ART. PARTICIPANTS/MATERIALS, SETTING, METHODS: The participants were equally randomised to one of four treatment arms: Group A (n = 28) received 100 mg CC (Day 3-7) and a starting dose of 450 IU HMG, Group B (n = 29) received 100 mg CC and a starting dose of 150 IU HMG, Group C (n = 30) received placebo and a starting dose of 450 IU HMG and Group D (n = 27) received placebo and a starting dose of 150 IU HMG. Serum levels of FSH, LH, estradiol and progesterone were measured on Day 1 and 5 and on the day of ovulation induction. Available embryos were cultured up to the blastocyst stage and were always transferred in the same cycle. The primary outcome was the number of oocytes collected after ovarian stimulation. Other outcome measures were response to ovarian stimulation, embryo development and obstetrical outcome. MAIN RESULTS AND THE ROLE OF CHANCE: All study participants (n = 114) fulfilled at least two of the Bologna criteria for poor responders. Median age of the study population was 38.5 years. There were 109 patients who underwent oocyte retrieval. The number of oocytes retrieved was similar among the groups (±SD; 95% confidence intervals); A: 2.85 (±0.48; 2.04-3.98), B: 4.32 (±0.59; 3.31-5.64); C: 3.33 (±0.52; 2.45-4.54); D: 3.22 (±0.51; 2.36-4.41); P overall = 0.246. However, ovarian stimulation with 150 IU plus CC resulted in a higher number of blastocysts compared to ovarian stimulation with 450 IU plus CC (±SD; 95% confidence intervals); A: 0.83 (±0.15; 0.58-1.2), B: 1.77 (±0.21; 1.42-2.22); P overall = 0.006. Mean FSH serum levels were lower in the groups with a starting dose of 150 IU. Adding CC did not affect mean serum FSH levels. There were no differences in estradiol concentrations among the groups. Endometrial thickness was lower in the groups receiving CC. The overall live birth rate (LBR) was 12.3%, and the cumulative LBR was 14.7%. LIMITATIONS, REASONS FOR CAUTION: The trial was powered to detect differences in neither the number of blastocysts nor the LBR, which would be the preferable primary outcome of interventional trials in ART. WIDER IMPLICATIONS OF THE FINDINGS: We found that ovarian stimulation with 150 IU gonadotrophin in combination with 100 mg CC produced more blastocysts. The effect of adding CC to GN on LBR in poor responders remains to be proven in randomised trials. High GN doses (450 IU) resulted in high FSH serum levels but increased neither the estradiol levels nor the number of retrieved oocytes, implying that granulosa cell function is not improved by high FSH serum levels. Lower starting doses of GN lead to a reduction of costs of medication. The small but significant difference in blastocyst formation and the lower FSH levels in the treatment groups receiving less GN may be an indication of better oocyte quality with higher developmental competence. STUDY FUNDING/COMPETING INTEREST(S): The costs for the HMG used for ovarian stimulation were provided by IBSA Switzerland. The study was also supported by the Repronatal Foundation, Basel, Switzerland. The authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: NCT01577472. TRIAL REGISTRATION DATE: 13 April 2012. DATE OF FIRST PATIENT’S ENROLMENT: August 2013.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Moffat R, Hansali C, Schoetzau A, et al. Randomised controlled trial on the effect of clomiphene citrate and gonadotropin dose on ovarian response markers and IVF outcomes in poor responders. Hum Reprod. 2021. PMID: 33367742. doi:10.1093/humrep/deaa336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。